Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

2.

Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients.

Damond F, Lariven S, Roquebert B, Males S, Peytavin G, Morau G, Toledano D, Descamps D, Brun-Vezinet F, Matheron S.

AIDS. 2008 Mar 12;22(5):665-6. doi: 10.1097/QAD.0b013e3282f51203. No abstract available.

PMID:
18317013
3.

Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use.

Brower ET, Bacha UM, Kawasaki Y, Freire E.

Chem Biol Drug Des. 2008 Apr;71(4):298-305. doi: 10.1111/j.1747-0285.2008.00647.x. Epub 2008 Feb 28.

PMID:
18312292
4.

Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France.

Drylewicz J, Matheron S, Lazaro E, Damond F, Bonnet F, Simon F, Dabis F, Brun-Vezinet F, Chêne G, Thiébaut R.

AIDS. 2008 Feb 19;22(4):457-68. doi: 10.1097/QAD.0b013e3282f4ddfc.

5.

In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors.

Desbois D, Roquebert B, Peytavin G, Damond F, Collin G, Bénard A, Campa P, Matheron S, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2).

Antimicrob Agents Chemother. 2008 Apr;52(4):1545-8. doi: 10.1128/AAC.01284-07. Epub 2008 Jan 28.

6.

Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.

Smith RA, Gottlieb GS, Anderson DJ, Pyrak CL, Preston BD.

Antimicrob Agents Chemother. 2008 Jan;52(1):329-32. Epub 2007 Oct 29.

7.

Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity.

Hamel DJ, Sankalé JL, Eisen G, Meloni ST, Mullins C, Gueye-Ndiaye A, Mboup S, Kanki PJ.

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1189-96.

PMID:
17961103
8.

Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naive patients in Burkina Faso.

Ruelle J, Sanou M, Liu HF, Vandenbroucke AT, Duquenne A, Goubau P.

AIDS Res Hum Retroviruses. 2007 Aug;23(8):955-64.

PMID:
17725411
9.

Antiretroviral drug-resistant HIV-2 infection--a new therapeutic dilemma.

Maniar JK, Damond F, Kamath RR, Mandalia S, Surjushe A.

Int J STD AIDS. 2006 Nov;17(11):781-2.

PMID:
17062187
10.

Commentary: decline of HIV-2 prevalence in West Africa: good news or bad news?

Eholié S, Anglaret X.

Int J Epidemiol. 2006 Oct;35(5):1329-30. Epub 2006 Jul 17. No abstract available.

11.

Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia.

Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, Corrah T, Whittle H, Vanham G, Rowland-Jones S, Janssens W, McConkey SJ.

AIDS. 2006 Jun 26;20(10):1455-8. No abstract available.

PMID:
16791023
12.

Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission.

Gottlieb GS, Hawes SE, Agne HD, Stern JE, Critchlow CW, Kiviat NB, Sow PS.

AIDS. 2006 Apr 4;20(6):895-900.

13.

Sixteen years of HIV surveillance in a West African research clinic reveals divergent epidemic trends of HIV-1 and HIV-2.

van der Loeff MF, Awasana AA, Sarge-Njie R, van der Sande M, Jaye A, Sabally S, Corrah T, McConkey SJ, Whittle HC.

Int J Epidemiol. 2006 Oct;35(5):1322-8. Epub 2006 Mar 16.

14.

Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

Boyer PL, Sarafianos SG, Clark PK, Arnold E, Hughes SH.

PLoS Pathog. 2006 Feb;2(2):e10. Epub 2006 Feb 17.

15.

[Efficacy and tolerance of antiretroviral therapy in HIV-2 infected patients in Dakar: preliminary study].

Ndour CT, Batista G, Manga NM, Guèye NF, Badiane NM, Fortez L, Sow PS.

Med Mal Infect. 2006 Feb;36(2):111-4. Epub 2006 Feb 15. French.

PMID:
16480843
16.

Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.

Rodés B, Sheldon J, Toro C, Jiménez V, Alvarez MA, Soriano V.

J Antimicrob Chemother. 2006 Apr;57(4):709-13. Epub 2006 Feb 7.

17.

CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort.

Matheron S, Damond F, Benard A, Taieb A, Campa P, Peytavin G, Pueyo S, Brun-Vezinet F, Chene G; ANRS CO5 HIV2 Cohort Study Group.

AIDS. 2006 Feb 14;20(3):459-62.

PMID:
16439883
18.

High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART.

Rodés B, Toro C, Sheldon JA, Jiménez V, Mansinho K, Soriano V.

AIDS. 2006 Jan 2;20(1):127-9.

PMID:
16327332
19.
20.

Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors.

Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S, Mammano F, Lastere S, Farfara I, Simon F, Chene G, Descamps D.

J Clin Microbiol. 2005 Jan;43(1):484-7.

Items per page

Supplemental Content

Write to the Help Desk